For Healthcare Professionals Outside the US

For adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection; for first-line treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation; for adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAF V600 mutation.

Choose Tafinlar + Mekinist to reduce your adjuvant patients’ risk of relapse and protect their QOL1,3,6

Learn more 

Nearly 1 in 5 patients with metastatic melanoma achieved a complete response with Tafinlar + Mekinist in the Phase III COMBI-v clinical trial4

See rates of disease control

Tafinlar + Mekinist is the first and only approved targeted therapy to treat adult patients with BRAF V600+ NSCLC1,2

Find out more 

OS, overall survival; QOL, quality of life.

References: 1. Tafinlar Summary of Product Characteristics. Novartis Pharmaceuticals Corp; 2018. 2. Mekinist Summary of Product Characteristics. Novartis Pharmaceuticals Corp; 2018. 3. Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377(19):1813-1823. 4. Robert C, Karaszewska B, Schachter J, et al. Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib + trametinib in patients with unresectable or metastatic BRAF V600E/K–mutant cutaneous melanoma. Presented at: ESMO 2016 Congress; October 7-11, 2016; Copenhagen, Denmark. 5. Robert C, Karaszewska B, Schachter J, et al. Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K–mutant cutaneous melanoma. Abstract presented at: ESMO 2016 Congress; October 7-11, 2016; Copenhagen, Denmark. 6. Data on file. Novartis Pharmaceuticals Corp; 2018.